Trials Sponsors Conditions Drugs Pricing

Conditions

NF2-related Schwannomatosis

Keywords

NF2-SWNHearing LossAuto-captioning glassesAugmented RealityNF2Neurofibromatosis Type IINeurofibromatosis Type 2

Outcome Measures

Primary Outcomes (1)

System Usability Scale
Used to assess the usability of the auto-captioning glasses, scored from 0-100, with higher scores indicating higher usability.
12 Weeks

Secondary Outcomes (2)

Modified Telehealth Usability Questionnaire (Satisfaction and Future Use Sub-scale)
12 Weeks
Self-Reported Device Use
12 Weeks

Study Arms (1)

Adults with NF2-SWN and Hearing Loss

EXPERIMENTAL

Adults with a clinical diagnosis of NF2-SWN and self reported hearing loss will use the auto-captioning glasses for 12 weeks

Device: Auto-captioning Glasses

Interventions

Auto-captioning GlassesDevice

Augmented reality glasses that overlay real time captioning on see-through lenses, allowing users to read what is being said out loud.

Adults with NF2-SWN and Hearing Loss

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Diagnosis of NF2-SWN by 2022 revised criteria
Age 18 years or older at time of consent

Sponsors & Collaborators

Massachusetts General Hospital
Otherlead

Study Sites (1)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

MeSH Terms

Conditions

Hearing LossNeurofibromatosis 2

Condition Hierarchy (Ancestors)

Hearing DisordersEar DiseasesOtorhinolaryngologic DiseasesSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsNeuroma, AcousticNeurilemmomaNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and Embryonal

Study Officials

Vanessa Merker, PhD
Massachusetts General Hospital
PRINCIPAL INVESTIGATOR

Enrollment

18 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: NONE
Purpose: OTHER
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Research Director, Family Center for Neurofibromatosis and Schwannomatosis

Study Record Dates

First Submitted

February 12, 2026

First Posted

February 19, 2026

Study Start

February 19, 2026

Actual (reported)

Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (1)

Adults with NF2-SWN and Hearing Loss

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (1)

Adults with NF2-SWN and Hearing Loss

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations